Tempus AI Partners with Daiichi Sankyo for Strategic Collaboration
Tempus AI announced a strategic collaboration with Daiichi Sankyo aimed at accelerating the clinical development and differentiation of an antibody drug conjugate program in oncology. Through this collaboration, Daiichi Sankyo will leverage Tempus' proprietary foundation models and AI expertise, including PRISM2, a state-of-the-art, multimodal foundation model that combines pathology images and clinical data to generate rich diagnostic and predictive insights. By combining clinical trial and preclinical research data from Daiichi Sankyo with Tempus' comprehensive real-world data, the collaboration aims to unlock new opportunities for biomarker discovery and patient stratification. Tempus and Daiichi Sankyo will develop proof-of-concept AI models to optimize patient selection and increase probability of success for a novel ADC. By deploying these models across Tempus' expansive oncology database, the collaboration will generate detailed response maps, enabling precise patient stratification and supporting rigorous benchmarking of potential control arms for future clinical trials.
